Holen Sie sich die Stockscreener-App
0.7161
1.32%
0.0093
InspireMD Inc. Aktie (NSPR) Neueste Nachrichten
InspireMD, Inc.(NasdaqCM: NSPR) dropped from Russell 3000E Growth Benchmark - marketscreener.com
NSPR Rallies After Hours On FDA Green Light for Key Stroke-Prevention Trial Despite Withdrawn Annual Guidance - Stocktwits
InspireMD, Inc.(NasdaqCM:NSPR) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Price to sales forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
Enterprise value to EBITDA forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
Enterprise value to revenue forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
Price to earnings forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
InspireMD Inc. Actuals & Estimates (NASDAQ:NSPR) - TradingView
NSPR Forecast — Price Target — Prediction for 2027 - TradingView
InspireMD Inc (NSPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InspireMD Inc (NSPR) Institutional Confidence - TradingKey
InspireMD, Inc. Announces Recalling of Cguard Prime Carotid Stent System 135Cm, 8Mmx30mm - marketscreener.com
InspireMD Inc (NSPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InspireMD Inc (NSPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InspireMD Inc (NSPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InspireMD Inc (NSPR) Valuation: PE, PB & Fair Value Analysis - TradingKey
InspireMD Inc (NSPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
InspireMD Inc (NSPR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
InspireMD Inc (NSPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR - Yahoo Finance
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
InspireMD announces inducement grants - Medical Buyer
InspireMD Inc. (NSPR) Holds at $0.73 After Fractional Gain, Testing Key Support ZoneStock Buy Zone - newsline.com
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NSPR Q1 2026 Earnings: EPS Beat Surprises on Strong Cost ManagementProfit Margin Analysis - newsline.com
Six new InspireMD employees receive 91,161-share stock grants - Stock Titan
InspireMD, Inc. (NSPR) reports Q1 loss, tops revenue estimates - MSN
InspireMD Reports Strong 30-Day Results From CGUARDIANS II Trial - TipRanks
Inspire announces 30-day CGUARDIANS II results; 100% acute device success, no 30-day MACEs - TradingView
Stroke-prevention stent hits 100% success in 50 high-risk patients - Stock Titan
InspireMD (NSPR) reports 100% device success in TCAR trial - Stock Titan
InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures - marketscreener.com
NSPR Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
NSPR Q1 2026 Earnings: EPS Surprises to the Upside Amid Limited Revenue VisibilityPost-Earnings Drift - newsline.com
InspireMD Initiates CGUARDIANS III Study for SwitchGuard Neuro Protection System in TCAR Procedures - Quiver Quantitative
InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures - GlobeNewswire
NSPR Q1 2026 Earnings: EPS Surprise of 12.85% Highlights Cost Discipline Amid Pre‑Revenue Stage - newsline.com
NSPR News | INSPIREMD INC (NASDAQ:NSPR) - ChartMill
InspireMD (NSPR) holders OK 250M authorized shares, re-elect directors - Stock Titan
InspireMD NSPR Q1 2026 Earnings Transcript - The Globe and Mail
NSPR Q1 2026 Earnings: EPS Surprises to the Upside, Stock Reacts PositivelyEstimate Revision Count - thelegaladvocate.com
InspireMD director Paul Stuka buys $17,500 in shares By Investing.com - Investing.com Australia
InspireMD (NSPR) Inches Higher as Shares Approach Key Resistance at $0.97Gap and Go - thelegaladvocate.com
InspireMD director Paul Stuka buys $17,500 in shares - Investing.com
Director Paul Stuka buys 20,000 InspireMD (NSPR) shares in open-market trade - Stock Titan
InspireMD anticipates FDA approval of original CGuard delivery system in Q3 2026 as it withdraws 2026 revenue guidance - MSN
InspireMD Inc. (NSPR) Q1 2026 Earnings: Narrower Loss Than Expected But Shares SlideEarnings Call Highlights - thelegaladvocate.com
InspireMD (NSPR) Slides 7.9% as Stock Tests Key Support Near $0.84RVOL Spike - The Legal Advocate
InspireMD (NSPR) Slides 8.4% to $0.87: Key Levels Under PressureEarnings Beat Stocks - newsline.com
InspireMD (NSPR) Slides 6.5% – Support Levels in Focus as Biotechnology Stock StrugglesATR Trailing Stop - dars.gov.et
InspireMD (NSPR) Q1 2026 Earnings: EPS Beat Despite Net Loss, Shares Dip 2.9%Post-Announcement Reaction - Newser
0.66%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):